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Introduction
Multiple myeloma (MM) is a malignant clonal plasma
cell disorder accounting for 1% of all cancers and 10% of
hematological malignancies.1 The main characteristic of the
disease is the clonal proliferation of plasma cells, and the
production, in the majority of cases, of a monoclonal heavy
and/or light chain immunoglobulin (M-protein).2 This disease
occurs in older population, with median age at presentation
of 65 years.3 Fewer than 2% of MM patients are under 40
years old at diagnosis.4 The survival of MM patients varies
from a few months to more then ten years, depending on
characteristics related to the disease itself (plasma cells
abnormalities, tumor mass, stromal factors), as well as to host
factors.5;6  These risk factors for the development and
progression of disease have been considered to be critical in
the comparison of outcomes within and between different
clinical trials. This strategy of assessing the patient according
to the presence of risk factors is important on an individual
basis, because it can predict the outcome. In addition, it
adequately stratifies the patients in clinical studies.7-10
Clinical, biological and molecular factors adversely
influence the outcome, and prognostic models have been
developed trying to stratify patient into groups of different
survivals.5;7;10-12
Prognostic assessment
The prognostic assessment has been based on risk
factors, and can be divided in:
The Durie/Salmon staging system continues to be used worldwide in patients with
multiple myeloma. However, in recent years, new systems have been proposed. The
International Myeloma Working Group performed a retrospective study with 11,179
patients and proposed an “International Staging System” utilizing serum levels of â2
microglobulin and albumin. In addition, current research has focused on the usefulness
of cytogenetic and molecular data as prognostic factors. These data suggest that these
parameters are powerful discriminators of a poor prognostic group of myeloma patients.
Indeed, these prognostic indexes have been utilized in clinical trials, with interesting and
encouraging results. Rev. bras. hematol. hemoter. 2008;30(Supl. 2):6-9.
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–  Clinical factors:
1. age distribution: poorer survival in older patients;
2. performance status
–  Factors related to the biology of the malignant clone:
1. cytogenetic and molecular abnormalities
2. proliferation index (high proliferative activity)
–  Tumor mass and organ damages:
1. renal failure (creatinine)
2. high serum levels of β2-microglobulin and C-reactive
protein
Since the development of the Durie/Salmon staging
system 3 decades ago, new prognostic models that include
these three groups of characteristics have been proposed.12
The Durie/Salmon staging system takes into account clinical
and laboratorial parameters, trying to estimate the tumor mass,
and consequently the prognosis. Analyzing the presence of
four factors at diagnosis (anemia, M protein, calcium and
lytic bone lesions) and presence of high serum creatinine
levels, this system divided MM patients in three defined
groups, with three different survival curves.
Looking for other prognostic markers, the level of β2
microglobulin showed to be an interesting prognostic factor
because it correlates with tumor mass and renal dysfunction.
The cutoff of 6 mg/L of ß2 microglobulin was able to divide
MM patients in two groups of different prognoses.13 In 2003,
the International Myeloma Study Group suggested another
staging system that incorporates the beta-2-microglobulin.
This system is easier than the Durie/ Salmon, and still predicts
the outcome.10 This staging system, called "International
Staging System" (ISS), was based on only two variables (β2-
microglobulin and albumin), and was able to define three
prognostic groups with different median survivals.
The C-reative protein is another marker of tumor mass
that has been used as prognostic factor. It has a good
correlation with tumor growth, and it is independent of the
β2 microglobulin levels. Another index score that incorporates
this marker is under study.15
Other factors that correlate with the outcome include
plasma cell morphology, type of bone marrow infiltration,
expression of adhesion molecules (CD56), high proliferative
activity, and angiogenesis.16-20
Recently, various cytogenetic abnormalities present in
the myeloma clonal cells were studied, and were strong
prognostic factors. By conventional cytogenetic analysis, at
least 39% of MM patients exhibit cariotypic abnormalities.21
With the use of tests with greater sensitivity, such as FISH
analysis, several abnormalities have been described, in a
greater proportion of patients.22 Deletions/monosomy of
chromosome 13, non-hyperdiploidy, and certain balanced
translocations (including chromosome 14) are predictors of
poor outcome.23-25 The deletion or monosomy of chromosome
13 represents the most prevalent abnormality, accounting for
50% of the abnormalities observed. This abnormality occurs
in 45% of patients with MM analyzed by molecular technique
(FISH analysis).24;26;27 and its presence is independently
associated with poorer survivals and duration of complete
remission.21
With the addition of all these new molecular profiles to
clinical variables, new staging systems may be even more
powerful to identify prognostic groups.
Data presented recently by the Intergroupe
Francophone du Myelome (IFM) showed a high incidence
of cytogenetic abnormalities, in agreements with other
studies, but they were able to identify three groups of patients
with different median overall survivals, according to β2
microglobulin levels and the presence of t(4;14) or del(17p).
The best overall survival was observed among patients with
β2 microglobulin levels <3 mg/L and absence of t(4;14) or
del(17p). This profile was observed in 35% of patients.
Patients with the worst overall survival (median 2 years)
comprised 15% of patients, and included β2 microglobulin
>3mg/L and the presence of either t(4;14) or del (17q). The
other 50% of patients belonged to an intermediate group.26
Clinical applicability
The rational of staging a patient is to quickly identify
high risk patients, and target the most appropriated therapy
for each case. Unfortunately, this is not yet standard of care,
but it is a matter of several clinical trials worldwide.7;25;27-30 A
recent study of the IFM based the treatment of MM on the
staging of the patients. It suggested dividing patients in
two groups, according to β2-microglobulin levels and the
presence of chromosome 13 deletion. High risk patients were
those with β2 >3 mg/L and the presence of del 13 by FISH
analysis.
Table 1. International Staging System (ISS)
Stage Criteria Median survival
(months)
I Serum β2 microglobulin < 3,5 mg/L and
                serum albumin > 35g/L    62
II Neither I or III    45
III Serum β2 microglobulin > 5,5 mg/L    29
The comparison between these two staging systems
showed that the ISS is better to define patients in stage I and
II than Durie/ Salmon, and that patients in stage III of the ISS
have worse prognosis than stage III of Durie/Salmon.10
The ISS has been validated on different settings of
patients and treatments of MM, including a recent analysis
among 1.112 Brazilians patients diagnosed during the past
seven years.14
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Patients without these high risk criteria were treated
with two consecutive stem cell transplants conditioned
with melphalan 140 mg/m2 and 200 mg/m2 (IFM 99-02).
Patients classified as high risk were enrolled in treatment
strategies that included higher doses of chemotherapy
(200 and 220 mg/m2 of melphalan), followed by two
autologous stem cell transplants (IFM 99-04) or one
autologous and one HLA-identical sibling dose-reduced
allogeneic transplant (IFM 99-03). The IFM 99-04 showed
that in high-risk patients, the dose intensity of melphalan at
420 mg/m2 led to encouraging results, but the addition of
anti-IL6 monoclonal antibody to the second conditioning
regimen did not improve the outcome.25 The IFM 99-02
showed that maintenance with thalidomide after the
autologous transplant resulted in an improvement in the
response rate, event free survival and overall survival in
patients without deletion of chromosome 13 and / or in those
with a beta-2 microglobulin < 3,0 mg/L.28
Treatment based on risk assessment has been also
proposed in a prospective studied by Brazilians researchers.
The treatment protocol includes a stratification based on
the presence of deletion of chromosome 13 and β2
microglobulin >2.5 mg/L (high risk). For patients without
high risk criteria, an induction remission with chemotherapy
(VAD) is followed by a single autologous peripheral blood
transplant using melphalan 200 mg/m2. Patients are then
randomized to receive maintenance treatment with
dexamethasone with or without thalidomide 200 mg/day.
For high risk patients, the protocol consists of a first
autologous transplant with melphalan 200 mg/m2, followed
by a second transplant with the same conditioning regimen,
or a dose-reduced allogeneic transplant if the patient has a
matched donor. After the second transplant, patients are
randomized to receive maintenance treatment with
chemotherapy (DCEP) + / - thalidomide. From October 2003
to January 2008, 229 untreated patients under 70 years old
were enrolled. The median observation time for whole group
was 22 months and for alive patients 24 mo (1-62). 44 out
179 (24%) died, most of them in VAD phase due to
progression. 135/179 (76%) are alive, ISS I 45/53 (85%), ISS
II 57/68 (84%) and ISS III 33/58 (57%) (p< 0.001). The OS in
60 mo by ISS was 76%, 75% and 36% for ISS I, II and III,
respectively (p< 0.0001). The EFS in 60 mo by ISS was 38%,
32% and 10% for ISS I, II and III, respectively (p< 0.0001).
The ANOVA showed significant difference for plasma cells
bone marrow infiltration, creatinine and hemoglobin levels
(p< 0.0001). The authors emphasized the importance of ISS
at diagnosis due to high capacity to discriminate among
groups with low cost. The protocol is still ongoing.
Conclusions and recommendations
Staging patients according to prognostic factors has
been the subject of several researches and has been used to
guide clinical trial protocols. In the future, this approach is
hoped to help in defining treatment regimens on a patient
basis, with a favorable impact on the prognosis.
The recommendation of recent guidelines on the
management of MM (4) includes:
1. The International Prognostic Index based on serum
albumin and β2 microglobulin in preference of Durie/Salmon
staging system.
2. Evaluate prognosis before starting treatment with,
as a minimum, serum levels of β2 microglobulin and albumin.
Cytogenetic and/or FISH analysis may be helpful if
available.
3. At present there is no evidence to support using
prognostic factors to choose therapy in individual patients.
Resumo
O esquema de Durie / Salmon continua a ser utilizado para estadiar
os pacientes com mieloma múltiplo. Recentemente, um novo siste-
ma mais simples e eficaz foi proposto. O "International Myeloma
Working Group" realizou um estudo retrospectivo com 11.179 pa-
cientes e a partir destes dados propôs a criação de um  "International
Staging System (ISS)" utilizando os níveis séricos de ß2
microglobulina e de albumina ao diagnóstico. Além do ISS a pes-
quisa está voltada para identificar alterações citogenéticas e
moleculares que se correlacionem com o prognóstico no mieloma
múltiplo. Estes fatores prognósticos têm sido utilizados para
estratificar pacientes em ensaios clínicos com resultados promisso-
res. Rev. bras. hematol. hemoter. 2008;30(Supl. 2):6-9.
Palavras-chave: Fatores prognósticos; mieloma múltiplo; biologia
molecular; tratamento.
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